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This scoping review analyzes the research gaps of three diseases: schistosomiasis japonica, malaria and echinococcosis.
Based on available data in the P.R. China, we highlight the gaps between control capacity and prevalence levels, and
between diagnostic/drug development and population need for treatment at different stages of the national control
programme. After reviewing the literature from 848 original studies and consultations with experts in the field, the gaps
were identified as follows. Firstly, the malaria research gaps include (i) deficiency of active testing in the public
community and no appropriate technique to evaluate elimination, (ii) lack of sensitive diagnostic tools for asymptomatic
patients, (iii) lack of safe drugs for mass administration. Secondly, gaps in research of schistosomiasis include (i)
incongruent policy in the implementation of integrated control strategy for schistosomiasis, (ii) lack of effective tools for
Oncomelania sp. snail control, (iii) lack of a more sensitive and cheaper diagnostic test for large population samples, (iv)
lack of new drugs in addition to praziquantel. Thirdly, gaps in research of echinococcosis include (i) low capacity in field
epidemiology studies, (ii) lack of sanitation improvement studies in epidemic areas, (iii) lack of a sensitivity test for
early diagnosis, (iv) lack of more effective drugs for short-term treatment. We believe these three diseases can
eventually be eliminated in mainland China if all the research gaps are abridged in a short period of time.
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Background
Schistosomiasis, malaria and echinococcosis are three
types of tropical diseases that threaten more than two
billion people worldwide [1-3]. These diseases mostly
affect poor rural communities in developing countries
[4] and those who are infected with such pathogens not
only suffer indisposition but also have various degrees of
morbidity, which induce poorer standards of living [5-9].
Continuous economic growth over the last 30 years
has allowed the government of the People’s Republic of* Correspondence: zhanghaobing@hotmail.com
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reproduction in any medium, provided the orChina (P.R. China) to continuously increased its budget
for parasitic disease control, resulting in a significant re-
duction in disease burden and transmission capacity
throughout the country [10-12]. Furthermore, an effective
national strategy has successfully brought down the preva-
lence levels of schistosomiasis japonica and malaria com-
pared to levels of 50 years ago [13-15]. Echinococcosis has
also been controlled to a stable level according to the five-
year national surveillance report made by the Ministry of
Health (MOH). Such achievements can be attributed to
political commitments, control strategies adapted to the
national control programme, as well as the innovative re-
search and research capacity building [16].
The major research achievements of last 30 years are
reflected in the progress in drug development, evaluation
of diagnostics with the national control programme and
the formation of a strong team for operational research,
providing the required information and tools for the na-
tional control programmes. Due to these diseases being
at various stages of the national control programme the
sensitivity of diagnosis is also different (See Figure 1). ItLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Different stages of the national control programme for three parasitic diseases in China.
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it will be an uphill struggle to reach the aim of elimin-
ation for schistosomiasis japonica and malaria in P.R.
China. Moreover, without a new strategy and technical
support, the currently controlled situation for echinococ-
cosis may worsen.
Review
The main purpose of this paper is to summarize and dis-
seminate relevant research findings on the three para-
sitic diseases, so as to identify research gaps in the
existing literature. A consultation study was undertaken
through the platform of Chinese Network on Drug and
Diagnostic Innovation (China NDI, www.chinandi.org.cn)
focusing on gaps (i) between research capacity and preva-
lence, and (ii) between diagnostic/drug R&D capacity and
population need for treatment at different stages of the na-
tional control programme.
Methods
Our scoping review uses an adapted version of the
ARKSEY and O’MALLEY (2005) framework [17], involv-
ing the following steps:
1. Identification and development of the research
questions.
The overarching research questions are as follows:
What is the gap between control capacity and
prevalence among these three diseases? What is the
gap between diagnostic/drug R&D capacity and
population needs for treatment at the different
stages of the national control programmes?2. Location, screening and selection of relevant
publications.
Terms were searched for in two most common
databases:PubMed database (http://www.pubmed.
com) and international articles from Medline
database, as well as the Wanfang database
(http://www.wanfangdata.com.cn) for Chinese
articles. Cqvip database, Cnki database and Wanfang
database are the three most popular Chinese
periodical databases in China. The percentage of
overlap in core journals of these three databases
is more than 95% in the research areas relevant
to this scoping review (biotechnology, medicine
and health). We selected the Wanfang database
after comparing the quality of information by
testing key words among three databases
mentioned abovea.
3. Publication selection
The searching procedure yielded 10,835 abstracts. A
team constituting of eight professional researchers
were responsible for publication selection. Level 1
relevancy testing went as follows:
1) Title, author and abstracts were scanned to
determine whether they were relevant with
epidemiology, diagnosis and chemotherapy of the
three parasitic diseases we focused on in China.
2) The study must have been launched in China and
include at least one Chinese author.
After the level 1 relevancy testing, 1677 citations
were identified for inclusion in this paper. Full
articles were then obtained for level 2 relevancy
testing. Team members selected and eliminated
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or treatment, vaccines, animal models, species
validation, surgical treatment and phylogenetic study.
Through this filtering, 860 articles were deemed
relevant and selected for inclusion. Of these articles,
12 were excluded in data extraction as they could not
classified into epidemiology, diagnosis and
chemotherapy by their full text. A total of 848 articles
were included in this research, with the review
process is outlined in Figure 2.
4. Data extraction.
The data extracted was consolidated in a ‘data
extraction form’ using a database programme, which
divided the three different diseases along three
research fields (epidemiology, diagnosis and
chemotherapy). We collated a mixture of general
information about the study along with specific
information relevant to our research and recorded
the information as follows:








This data formed the basis of the analysis. We
sought a uniform approach to all 848 studies
included in the review. In practice we found out that
approximately 8% of the included articles did not
present all the information we needed.
5. Consultation exercise.
As indicated in the background, this scoping study
also included a consultation element. Since 2010,Figure 2 Results of the search strategy. (Abbreviation: Ma instead for Malaria;more than 300 scholars attended our public
meetings to discuss drugs, diagnostics innovation
and control for tropical diseases in China. The
minutes of these meetings were extracted for gap
analysis and considered in comparison to the
literature review.
6. Collating, summarizing and reporting the results
Once the outlined steps were completed, we were
able to present our narrative account of findings.
Particular attention was given to a basic numerical
analysis of the studies included in the review. Since
there was great diversity and/or overlaps among
reports, we rejected much of the very detailed
information in order to make the table clearer. We
hope these tables can present readers with an
intuitive impression of the three diseases in China.
In addition the team evaluated the full text of each
paper and supplementary information was collated
in the corresponding summary table.Result
Gaps between research capacity and disease prevalence
After we extracted and analyzed the chosen articles, the
relevant data was collected and summarized for thematic
findings from the full text of the articles (Table 1).Malaria
Prevalence In 2011, there were 4479 malaria cases
reported through the infectious diseases reporting sys-
tem from 782 counties of 27 Provinces in P.R. China
(total 2856 counties of 31 provinces). 68.9% of the reported
cases were in Yunnan, Anhui, Jiangsu, Henan and Sichuan
provinces [18].Sj instead for Schistosomiasis japonica; Ec instead for Echinococcosis).




Survey population range Epidemic data







Survey for humans 154 13 (15.1%) 27 (31.4%) 24 (27.9%) 21 (24.4) 1 (1.1%) 110958 0.06% 0.00062% (0-0.2%)
Survey for mosquito 6 0 2 (33.3%) 2 (33.3%) 2 (33.3%) 0 72776 - 0.009%
Survey for animal
(definitive host)
1 1 (100%) 0 0 0 0 328 3.4% -
Schistosomisis (238)
Survey for human 238 53 (22.2%) 86 (36.1%) 61 (25.6%) 33 (13.8%) 5 (2.1%) 192061 14.2% (0–60.1%) 3.5 % (0–17.9%)
Survey for Oncomelania
hupensis
61 9 (14.7%) 18 (29.51%) 18 (29.51%) 13 (21.3%) 3 (4.9%) 57251 - 0.26% (0-1.2%)
Survey for animal
(definitive host)
75 23 (30.6%) 26 (34.6%) 18 (24.0%) 8 (10.6%) 0 (0.0%) 49773 - 3.81% (0–28.5%)
Echinococcosis (68)
Survey for human 68 21 (30.9%) 41 (60.3%) 6 (8.8%) 0 0 6022 20.8% (8.9-55.2%) 7.40% (0.15%-29.3%)
Survey for pika, mice,
livestock
40 21 (62.5%) 13 (35.0%) 1 (2.5%) 0 0 4016 - 24.9% (2.4%-54.9%)
Survey for animal
(definitive host)
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lished by the Ministry of Health of P.R. China, the number
of total malaria cases reported has declined significantly
over the past ten years (Figure 3). Yet imported malaria
cases began to dominate and became prevalent throughout
the country after almost two years [19]. The imported
malaria cases accounted for 66.4% of total malaria cases
in 2011.
Gaps in eliminating malaria When the goal for the na-
tional malaria control programme changes from control to
elimination, the strategy on target population and control
methods will need to be revised accordingly [20,21]. There
are two gaps identified in eliminating malaria.
Gap 1: Lack of active surveillance in the public
communities.
In the pre-elimination control stage, malaria
carriers may be the main source of infection in
the remaining epidemic area [22,23]. According
to this research, only 5% malaria articles are
relevant to active surveillance in the epidemic
area. This condition was also identified from
the national survey of malaria in 2010. In that
year, the population tested for malaria in fever
clinics was 7.1 million, while the field site
survey population was only 0.14 million.
Therefore, we recommend that more active
surveillance activities be put in place to
diagnose malaria carriers in suspicious residual
epidemic sites in the future.
Gap 2: There is no appropriate technique to effectively
evaluate elimination.
When indigenous malaria cases decreased
sharply, the proportion of imported cases of
falciparum malaria accounted that for all malaria
cases increased from 1.5% in 2003 to 31.6% in
2011[10,18,24-29]. However, there are still noFigu
japo
Figure 3 New Case Report of malaria in China
(Year 2004–2012).articles relevant to the technique that can
accurately distinguish imported cases from local
cases [30]; this has also led to the problem of
judging between new cases and recurring cases. In
the later stage of malaria elimination, it is difficult
to evaluate whether an area has really eliminated
malaria or not. Thus, effective biomarkers
urgently need to be developed in order to
distinguish imported cases from local cases.Schistosomiasis japonica
Prevalence In China, schistosomiasis japonica was epi-
demic throughout 12 provinces after liberation in the
1950s. By 1995 five provinces had blocked the transmis-
sion of Schistosoma japonicum [31]. However, transmis-
sions still occurred in provinces along the Yangtze River
and its southern areas in 2010, particularly in Hunan,
Hubei, Jiangxi, Anhui and Jiangsu, and in the mountain-
ous and hilly regions of Sichuan and Yunnan provinces.
From 2004 to 2012, the number of acute cases of schis-
tosomiasis japonica reported has dramatically declined
from 816 to 13 [32-39] (Figure 4). However, there are
still approximately 68 million individuals at risk [39].
In this study, 238 articles were judged relevant to epidemi-
ology of S. japonicum in China. In Table 1, the average
number of each survey article for human, Oncomelania
sp snail and definitive host in animals are respectively
192061, 57251 and 49773. In these articles, most of the
studies are reported from the 12 provinces mentioned
above. To support the large amount of surveillance work
that is needed to collect this information, China has thou-
sands of professional staff responsible for the supervision
and control of schistosomiasis japonica. For Hunan prov-
ince, the Hunan Institute of Parasitic Diseases (HIPD) is
an important guarantor of schistosomiasis control work
throughout the province. The institute has over 400re 4 The number of acute cases of schistosomiasis
nica in China (Year 2004–2012).
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for treating patients with schistosomiasis [40].
Gaps in controlling schistosomiasis japonica
Gap 1: Present policy cannot completely ensure the
execution of an integrated intervention strategy
for schistosomiasis control.
In China the national control programmes for
schistosomiasis japonica is now at the
transmission control stage. The goal at present
is to decrease the schistosomiasis infection rate
to 1% by 2015. Chinese authorities have also
discussed the possibility of achieving
elimination of schistosomiasis japonica by the
year 2020. To realize these goals, a four-
pronged approach has been investigated since
2008 [41,42]. The objective of the approach is
to interrupt the environmental contamination
of schistosome eggs as follows: First, replace
buffaloes with tractors. Second, restrict
marshland used for pasturing and encourage
fenced cattle-farming. Third, improve sanitation
facilities in houses. Fourth and last, provide
toilets for mobile populations (e.g. fishermen).
In general, the integrated measures for
schistosomiasis japonica control with an
emphasis on controlling the sources of
infection have had strong effects [43-45].
However, in some less developed areas -
particularly regions retaining traditional
customs of using buffaloes for farming -
considerable resistance has been faced for
implementation because the strategy is contrary
to the interests of the local economy [46-48].
Some marshland is still contaminated by
infected cattle and many residents are under
threat of schistosomiasis japonica [29].
Gap 2: Lack of effective tools for Oncomelania sp. snail
control.Figure 5 New Ccse reports of echinococcosis in P.R China
(Year 2004–2012).The habitat environment of the Oncomelania
sp. snail in China has seen no significant
change during the last 5 years [38,49,50].
Oncomelania sp. snails can proliferate in many
kinds of habitat. In 2010, the total habitat area
with snails was about 1608.7 million M2,
presenting an ambitious task for elimination by
manpower [51]. Three factors boost the
expansion of the infected Oncomelania sp.
snail’s habitats. 1) Unpredictable flooding of the
Yangtze River. 2) More than 40 species of
mammals that can act as reservoir hosts. 3)
Millions of migrating people including patients
moving to non-endemic rural areas. Suchtrends may threaten those non-endemic areas
[52-56]. For this reason, the control of
schistosomiasis japonica is not steady and can
easily see repeated outbreaks. A new
Oncomelania sp. snail control technique should
be developed, for example, to find its natural
predator or develop a biotechnological method
to induce infecundity [57].Echinococcosis
Prevalence In China, new cases of echinococcosis have
been increasing continuously since 2004 (Figure 5). The
population at risk is approximately 66 million. The na-
tional survey of important parasitic diseases in 2004
showed that the average prevalence rate for populations
in endemic areas was 1.08% [58]. From 2004 to 2008, 27
provinces out of 31 had reported cases of echinococcosis
and 98.2% of the reported cases were in Inner Mongolia,
Tibet, Gansu, Qinghai, Ningxia, Xinjiang and Sichuan
province [58].
Echinococcosis is also a kind of zoonosis [59]. According
to the “Prevention and treatment of echinococcosis Ac-
tion Plan (2010–2015)”, the number of infected livestock
in P. R. China amounts to about 50 million every year.
Thus echinococcosis is one of the main reasons leading
a large amount of herdsmen to poverty [60].
Gaps in control of echinococcosis
Gap 1: Low capacity for controlling echinococcosisAccording to Chinese echinococcosis control
policy, it is important to treat each dog in
epidemic areas every month to control the
main infection source [61,62]. The strategy is
actually relatively straightforward, but the
execution is very hard considering the
enormous amount of dogs in these pasturing
areas, which cover 40% of land in P.R. China
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knowledge and are reluctant to change their
living habits, such as feeding flesh viscera of
sheep to dogs and touching dog fur [66-69].
Gap 2: Manpower restrictions in field survey.
According to the studies of echinococcosis in
relevant papers, the total and average survey
population (6,022) is far less than for the other
two diseases (192,061 and 110,958). A low
population density in epidemic areas, along
with manpower restrictions are the main
reasons for this situation occurring. It is
imperative to train a larger number of
echinococcosis researchers and improve their
remuneration for these epidemic areas.
Gap 3: Not enough support for hygiene and sanitation
in high transmission areas.
In high-transmission regions, the hygiene and
sanitation conditions are usually unsatisfactory
[70,71]. Most of these areas lack access to tap
water; households collect water several times a
day from contaminated lakes or rivers for
personal use and drinking without boiling
[72,73]. In addition the limited supply of water
is not sufficient enough for washing hands
[72,73]. These risk factors are hard to change
for certain living environments and industries,ble 2 Diagnosis data collected from relevant articles for three m
Disease Immunodiagnosis method Research in fieldsurvey
Disease Total Type (n) Sensitivity Specificity Population Total
Malaria
26* GICA(9) 88.4-95.5% 95.7-100% 547 35
ICA(14) 74.2-98.6% 91.3-100% 938
PCR(10) 96.1-99.6% 98.8-100% 167
LAMP(2) 98.3-98.8% 100% 46
histosomiasis
55* COPT(3) 90.0-91.8% 95.3-97.4% 89 52
DDIA(8) 75.3-97.1% 55.1-99.0% 755
DIGFA(9) 92.0-100% 92.2-97.5% 556
ELISA(25) 65.8-98.4% 51.7-100% 716
IHA(32) 69.6-97.3% 63.6-97.8% 743
PCR(4) 100% 100% 52
Others(6) 85.5-98.5% 76.3-97.0% 85
hinococcosis
9* IHA(4) 87.1-92.7% 69.5-91.6% 315 24
DIGFA(2) 56.7-93.2% 79.1-95.0% 180
ELISA(8) 59.3%-91.2% 93.8-100% 289
Others(3) 32.5%-76.9% 41.3-81.6% 42
te: *More than one diagnosis method was used in one article.
breviation: COPT Circum oval precipitating test, DDIA Dipstick dye immuno-assay, DIGFA
say, IHA Indirect hemagglutination assay, ELIB Enzyme-linked immuno-electrotransfer bl
say, LAMP Loop-medicated isothermal amplification.especially in poor domestic economic
situations.Gaps between diagnostic/drug development and
population need for treatment
Relevant data has been collected and summarized to find
the research gaps in diagnostic/drug development in the
three diseases (Tables 2 and 3).
Gaps in diagnostic development
Gap 1: Lack of malaria sensitive diagnostic tools for
asymptomatic patients and patients at low
levels of parasitemia.
There were 61 papers that introduced the
diagnosis of malaria. The availability of rapid
diagnostic tests has made it possible to improve
and expand diagnostic testing for malaria. In
field surveys, PCR and LAMP diagnostic tools
have the highest sensitivity (96.1-99.6%) and
specificity (98.8-100%), but high cost and new
technical requirements are obstacles for wider
use [74]. GICA as a diagnostic tool appears to
be the popular area in research and
development as it is easy to use and has a lower
cost, but the level of sensitivity is not
satisfactory (88%-95%). We concluded fromain parasitic diseases in China












41 11 44/52 8/52
DIGFA (6) 8 16 5/24 19/24
Dot immunogold filtration assay, ELISA Enzyme-linked immunosorbent
ot, ICA immunochromatographic, GICA Gold immunochromatography
Table 3 Chemotherapy data collected from relevant articles for three main parasitic diseases in China
Disease Article (n)
Clinical trial for MOH Recommended drug Drug development













Schistosomiasis 22 Praziquantel (22) 74.7%-100% 221 (33–615) 42 0 42/42 0/42
Echinococcosis 11*
Albendazole emulsion (7) 57.1%-83.1% 95 (36–264) 11 9 11/20 9/20
Albendazole tablet (6) 15.8%-31.3% 57 (24–108)
* More than one kind of drug can be studied in one article.
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tested by blood smears. This indicates that the
diagnostic kit currently available on the market
has not met the requirements of epidemic
areas. A new diagnosis kit is needed for P. vivax
with two components during pre-elimination
stage. Firstly, it should have a high accuracy for
low parasitemia density patients (both
sensitivity and specificity should more than
95%). Secondly, it needs to detect G6PD
deficiency (Glucose-6-phosphate dehydrogenase
deficiency) because antimalarial drugs as
primaquine, pamaquine, and chloroquine can
cause acute haemolysis in people with G6PD
deficiency [75].
Gap 2: Lack of a more sensitive and cheaper diagnostic
test for S. japonicum infection of large
population samples.
There were 107 papers introducing the diagnosis
of schistosomiasis japonica. ELISA and IHA are
the most common methods used on field sites.
However, DIGFA has proved to have better
sensitivity and accuracy. Therefore it is anticipated
to be the future candidate used in large-scale
surveys. In the research and development area,
researchers focus on candidate-finding in
recombination protein. This tendency is
supported by the achievement of whole-genome
sequencing of S. japonicum in China.
More than 80% of field surveys in China use
immunodiagnostic kits combined with faecal
examination. Antibody detection is very useful
in screening for large-scale endemic surveys, in
order to quickly acquire the baseline infection
rate of schistosomiasis japonica. Faecal
examination is recommended for determiningthe character that antibodies persist after
parasitological cure. Moreover, microscopy may
also miss infections, especially for those who
are only moderately infected and in areas of
low transmission [76-78]. Since an enormous
amount of samples are to be identified for
schistosomiasis elimination in the near future,
the ideal diagnosis method should be more
sensitive and significantly cheaper than any of
the presently available methods.
Gap 3: Lack of sensitive test for early diagnosis of
echinococcosis.
In China, ultrasonography is the most frequently
used test for echinococcosis diagnosis [79,80].
Immunodiagnostic tests are also widely used in
fieldwork. The kits used most widely are the
ELISA-based serological tests, using either an
Echinococcus granulosus hydatid cyst fluid
antigen or an E. multilocularis crude vesicular
fluid for primary screening. The sensitivity for
hepatic cases of CE (Cystic echinococcosis)
ranges from 85% to 98%. For AE (Alveolar
echinococcosis), the use of purified or
recombinant E. multilocularis antigens exhibit
high diagnostic sensitivities ranging from
between 91% and 100%, with overall
specificities of 98%–100% [81]. However, for
echinococcosis formed in other organs except
for liver, the specificities are less than 50%.
DIGFA seems to be the current area of interest
for research and development.
In general, more imaging procedures should be
used in echinococcosis epidemic areas to
diagnose patients. For Immunodiagnostic tests,
the gap is to develop new serological tests with
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then bring them to a world standard. The
resulting drug should also be straightforward
and cheap to produce, with the capacity to
diagnose early stage echinococcosis and allow
for early treatment.Gaps in drug development
Gap 1: Lack of safe drugs for both mass production
and active again hypnozoites of P. vivax.
Antimalarial drugs are essential in moving from
control to elimination [82]. A 8-day therapeutic
schedule by using chloroquine plus primaquine
for P. vivax has now replaced the old schedule
for 21-days and 14-days in China. The patient
cure rates for 8-days chemotherapy is 96.9%-
100%. Also an artemisinin-based combination
therapy is widely used in China to treat P.
Falciparum with cure rate of 82.4%-100%. Still,
no new drug has been successfully developed in
the past 10 years in China.
P.vivax was detected in more than 99% of local
malaria cases diagnosed microscopically. A
characteristic of P. vivax infections is relapses
originating from hypnozoites. There is a need
for a radical cure to abate the source of
infection during the course of malaria
elimination [83]. New drugs are to bee 4 Gaps of control capacity and diagnostic/drug developm
ses No. Gap from consu
ia 1 Need new diagn
2 Need innovative
3 Lack of techniqu
4 Difficulty in findi
5 Need new surve
6 More focus on t
osomiasis japonica 1 Need higher sen
2 Need new drug
3 Need new mollu
4 Difficulty in testi
5 Need innovative
6 Difficulty in cont
ococcosis 1 Need effective d
2 Need financial su
3 Need long-actin
4 Need effective v
5 Need more sens
6 Control of the wdeveloped for hypnozoites and should be safe
for patients with G6PD deficiency.
Gap 2: The public needs a new drug for prophylactic
treatment of schistosomiasis.
Praziquantel is the sole drug for treatment and
morbidity control of schistosomiasis japonica.
Praziquantel is safe, cheap and effective against
adult worms. In China, cure rates of up to 85–
95.3% have been achieved but complete cures
(100%) are seldom. Praziquantel does not
prevent reinfection because it’s effects only last
a few hours and it cannot kill immature worms
[84]. Artemether was proved to kill immature
worms over the first 21 days post inoculation in
laboratory [85,86], yet there has been no
further research to support its application and
dissemination in large-scale chemotherapy
combined with praziquantel for anti-
schistosoma japonicum.
Many animal experiments have been
conducted using mefloquine for anti-
schistosomiasis [87-89]. The results indicate
that mefloquine exhibits an extensive and
severe damage both to juvenile and adult
S. japonicum harbored in mice. Nevertheless,
this is still a long way from field application
when there is a public need also for a new drug
in addition to praziquantel. Firstly, the new
drug is required to be cheap, safe and effectiveent presented in total 4 consultation meetings
ltation
osis method for asymptomatic patients
and safer drugs
es to distinguish abroad-imported cases from indigenous cases
ng asymptomatic patients
illance system for pre-elimination period
he continuously increasing imported cases
sitive antigen testing
which can prevent reinfection
scicide with less negative impact on the environment and biodiversity
ng for a moving population
surveillance-response approaches system
rolling for more than 40 hosts
rug for short-term treatment
pport for hygiene and sanitation in epidemic areas
g antihelmintic implants or drugs to control dog infection
accine for people in epidemic areas
itive serological test for field survey
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administration. Secondly, it should not
produce the cross-resistance with praziquantel.
Thirdly, it will preferably be effective against
both juvenile and adult worms.
Gap 3: Lack of a more effective drug for a short-term
treatment of echinococcosis.
In China, more than 94% echinococcosis
patients were treated by chemotherapy, with
only 6% of patients requiring an operation.
Changing the dosage forms of albendazole
tablets is the main achievement in
echinococcosis chemotherapy in China [90,91].
Both albendazole emulsion and liposomal
albendazole have proved more effective than
albendazole tablet for E. granulosus [92-94].
However, there are shortages in the currentble 5 Recommendations for overcome gaps of control capacity
ticle
iseases Research area of gaps Specific gaps
alaria Epidemic control Need more active surveillance for
early detection
No appropriate techniques to evaluate
elimination
Diagnosis Need new diagnosis method for
asymptomatic patient
Chemotherapy Need innovative and safer drugs
histosomiasis
onica
Epidemic control Need effective tools for Oncomelania sp.
snail control
Need policy support to protect the
execution of control strategy
Diagnosis Need more sensitive and cheaper
diagnostic test for large population
sampling.
Chemotherapy Need new drugs in addition to
praziquantel.
hinococcosis Epidemic control The execution for control echinococcosis
is not satisfying.
Manpower restrictions in echinococcos
control
Not enough support for hygiene and
sanitation in epidemic areas.
Diagnosis Need more sensitive test for early
diagnosis
Chemotherapy Need more effective drug for short-term
treatmentchemotherapy approach as it is a long course of
treatment (at least 3 months lifelong) and has
relative low cure rates (8.2%-74.5%) [94-96]. An
adverse effect rate of more than 20% is another
main reason for patients to give up their
medicine course [97,98]. Therefore, a new more
efficient drug urgently needs to be developed.Gaps identified by consultations
The minutes of four consultation meetings were extracted
into a list of the most important gaps presented by ex-
perts. This list in addition to the full text of included arti-
cles provides further detail to our study (See Table 4).
Discussion
The choice of scoping framework in the article through
gap identification is based on our previous experience ofand diagnostic/drug development reported in this
Recommendation for overcome gaps
More precise prediction by statistical model and geographical
information systems (GIS). Set up active surveillance and
response system to prevent reestablishment of transmission.
Set up clonal germplasm repository for plasmodium and its
vectors. Find specific biomarker to distinguish different
geographic strain.
Find new candidate biomarkers. Quality sampling for diagnostic
kits before large-scale testing in field.
Accelerate the validation and standardization for candidate drugs.
Strengthen international cooperation in new drug development.
Develop diagnostic assays for the large-scale screening of
specific snails. Use GIS for prediction of snail distribution.
Develop new snail interventions.
Coordinate by local government. Give full administration
enforcement rights to the Chinese Center for Disease Control
and Prevention.
Find new candidate biomarkers. Focus on innovation of
immune complex dissociation procedure to increase the
sensitivity of detection.
Accelerate the validation and standardization for candidate drugs.
Strengthen international cooperation in new drug development.
Coordinate by local government. Give proper administration
enforcement right to the Chinese Center for Disease Control
and Prevention.
is Larger personnel force for echinococcosis control. More
professional training for echinococcosis control.
Government increase in financial support on hygiene and
sanitation improvement in these areas. Strengthen health
education on echinococcosis prevention.
Undertake a comparative study of all the available antibody
detection to form guidelines for large-scale scanning. Find new
candidate biomarkers.
Accelerate the validation and standardization for candidate
drugs. Focus to develop new form of benzimidazole to
improve its bioavailability. Strengthen international cooperation
in new drug development.
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identification and development of key research questions.
The questions concern location, screening and selection of
relevant publications; publication selection; data extrac-
tion; collating, summarizing and reporting the results. The
resulting research gaps reported in our study also relied
on two main sources. First, the literature review from
which we extracted the papers to use and then summa-
rized information from selected papers. Second, the gaps
extracted in consultation. Overall we have identified, sum-
marized and reported on about 13 research gaps in this
paper. Experts in this study then gave corresponding ad-
vice on how to overcome gaps (See Table 5).
In this research, we endorse a consultation element to
enhance a scoping review study. Choosing this route can
enhance the veracity of final gap analysis and also ensure
that the results more practically applicable. For instance,
in the consultation meetings, experts presented the idea
that P.R China needed a new technique to evaluate mal-
aria elimination. Since P. R. China announced the object-
ive to eliminate malaria only two years ago, few papers
mentioned this gap. If we used a traditional systematic re-
view, we may have not identified more immediate and
forward-looking research gaps. Although such an element
may be considered an ‘optional extra’ for scoping review,
the consultation exercise did indeed provide ‘added value’
to the literature review. The limit of this research is in the
deficiency of vaccine analysis. We do not have any profes-
sional team members working on the vaccine area. Our
concern was in giving a fair evaluation on the part of vac-
cine research and therefore we have not incorporated vac-
cine research into the theme of the study.
When comparing the research priorities among the
three diseases, malaria, schistosomiasis and echinococco-
sis, in aspects of diagnostics and drugs the major differ-
ence was found in two areas. One is the requirements of
sensitivity and specificity in diagnosis, and the other is ef-
fectiveness of drug treatment, due to the different stage of
the diseases control programme. For instance, for the pre-
elimination stage of malaria, higher sensitivity and specifi-
city diagnostics is needed both in individual and in
population diagnosis [99]. At the same time, the tools used
in the certification of malaria elimination, also needs to be
further developed [100]. This is a concern as to the fact
that innovative drugs or drug combinations are given a
higher priority to reduce the risk of drug resistance
[101,102]. For the transmission control stage of schisto-
somiasis, it is necessary for high sensitivity tools to screen
the at risk population, in order to guide the MDA or se-
lective chemotherapy based on different endemicity levels
and further reduce transmission risks [5,77,78]. New drugs
need to be developed for prophylactic treatment to effect-
ively for target all stages of the parasites [2]. For the mor-
bidity or infection control stage of echinococcosis, it isnecessary to develop the early diagnostics, for individual
and population uses [103]. Effective drugs with a short-
time chemotherapy also requires development [3]. Both
early diagnostics and short-time schemes for the effect-
ive treatment will contribute significantly to the reduce
burden of disease [104]. Therefore, this comparative ap-
proach provides a clear indication of the diagnostic
drugs that are necessary to be used in the different
stages of the control programme.
The major problem has been that investment into the
national control or elimination programmes has fallen
after the burden of disease. We suggest that sustained
investment in the development of diagnostics and drugs
is required. This needs to be well budgeted for at all
stages, with the argument put to policy makers that a
marginal effect applies in the different stages of the na-
tional control programme, whether it be from morbidity
or infection control to elimination.
Conclusions
Today, although some areas of research on schistosom-
iasis japonica, malaria and echinococcosis have been
neglected, they are now attracting high levels of concern
from many nations, including P.R China. The govern-
ment is providing sustained financial and technical sup-
port underpinned by key control targets. Thus we
believe these three diseases can eventually be controlled
or eliminated in mainland China following years of
sustained efforts.
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